Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 9Active not recruiting 5Recruiting 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Cyclophosphamide 8Vincristine 7Prednisone 6Specimen Handling 5Rituximab 5Doxorubicin 5zanubrutinib 3prednylidene 3deltacortene 3Magnetic Resonance Spectroscopy 3tazemetostat 2fludarabine phosphate 2fludarabine 2Radiotherapy, Intensity-Modulated 2Melphalan 2Etoposide 2Drug Therapy 2CT-P10 2Biopsy 2Azacitidine 2Antibodies, Monoclonal 2vactosertib 1tisagenlecleucel 1sargramostim 1ponatinib 1pembrolizumab 1obinutuzumab 1mogamulizumab 1glucarpidase 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Methods × Lymphoid × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡